09.12.26 -- Pharmaceutical Online Newsletter - Best Of August

Is your organization ready for the revised USP <87>? Join Pace® Life Sciences to explore anticipated changes to biological reactivity testing and what they could mean for material qualification, validation, and compliance. Gain practical insights into evolving regulatory expectations, testing readiness, and strategies to support a smooth transition ahead of the December 1, 2026 release. Click here to learn more. 

Several advantages explain why Puerto Rico continues to attract pharma investment, especially as manufacturers reassess supply chain risk and look for options closer to the U.S. mainland.

In a Pharmaceutical Online Live discussion on building inspection-ready systems with digital documentation, panelists emphasized that AI can accelerate review, trend analysis, and inspection response, but only when governed, validated, and kept firmly under human quality oversight.

Mathini Ilancheran updates us on how delayed U.S. tariffs on generic drug imports could reshape supply, sourcing, and trial planning.

Smarter email habits cut wasted time, reduce inbox noise, and improve collaboration. Clear subject lines, careful recipients, and purposeful tool use keep teams focused on meaningful work.

Increasing mAb complexity is pushing purification beyond traditional platforms. See how flexible chromatography, optimized buffers, and adaptable workflows are becoming essential to achieve purity.

USP <86> introduces validated recombinant alternatives for endotoxin testing, supporting animal-free QC. Learn key validation, comparability, and regulatory considerations.